The VHIO Epsilon test, developed by the Cancer Genomics Group at VHIO, is designed to detect fusions and analyze gene…
featured news home
Published in The Lancet, final overall survival results of the phase 3 TALAPRO-2 trial show that talazoparib plus enzalutamide significantly…
As part of its strategic vision, the Vall d’Hebron Institute of Oncology (VHIO) is actively involved in a wide range…
Results of a study led by VHIO’s Prostate Cancer Group suggest that treatment with CDK4/6 inhibitors followed by senloytic therapies…
A group of 34 international leading experts in hepatology, data science, and artificial intelligence (AI) has released a consensus report…
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—together with the…
For the fourth consecutive year, the Iker Association donated to myxoid liposarcoma research at VHIO. This association aims to promote…
The European Research Council (ERC) Proof of Concept (PoC) Grants provide funding to researchers who have previously received an ERC…
Today we launch a new episode of the Cancer360º podcast to discuss the potential role of the microbiome in cancer…
On 13 June, we paid tribute to the Endavant Chic@s Association by presenting them with a commemorative plaque. This was…
